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Abstract
To detect food E. coli O157:H7 contamination rapidly and accurately, it is essential to prepare high specific monoclonal
antibodies (mAbs) against the pathogen. Cyclophosphamide (Cy)-mediated subtractive immunization strategy was
performed in mice to generate mAbs that react with E. coli O157:H7, but not with other affiliated bacteria. Specificity of 19
mAbs was evaluated by ELISA and/or dot-immunogold filtration assay (DIGFA). Immunogloubin typing, affinity and binding
antigens of 5 selected mAbs were also analysed. MAbs 1D8, 4A7, 5A2 were found to have high reactivity with E. coli O157:H7
and no cross-reactivity with 80 other strains of bacteria including Salmonella sp., Shigella sp., Proteus sp., Yersinia
enterocolitica, Staphylococcus aureus, Klebsiella pneumoniae, Citrobacter freundii and other non-E. coli O157:H7 enteric
bacteria. Their ascetic titers reached 1:10
6 with E. coli O157:H7 and affinity constants ranged from 1.57610
10 to 2.79610
10 L/
mol. The antigens recognized by them were different localized proteins. Furthermore, immune-colloidal gold probe coated
with mAb 5A2 could specifically distinguish minced beef contaminated by E. coli O157:H7 from 84 other bacterial
contaminations. The Cy-mediated subtractive immunization procedure coupled with hybridoma technology is a rapid and
efficient approach to prepare discriminatory mAbs for detection of E. coli O157:H7 contamination in food.
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Introduction
E. coli O157:H7, a species of enterohemorrhagic E. coli, is the
bacterium that causes diarrhea. E. coli O157:H7 outbreaks have
become a severe threat to human health. In 1993, more than 700
people in the USA were infected with E. coli O157:H7 con-
taminated Jack in the Box hamburgers. In August 1997, Hudson
Foods, a major hamburger supplier for Burger King, recalled 35
million pounds of ground beef (the largest food recall in the
nation’s history), as a result of a major E. coli O157:H7 outbreak
(http://www.downtoearth.org/health/general-health/rise-food-
poisoning-america). In 1996, the most serious E. coli O157:H7
infection in the world occurred in Japan and resulted in 10 deaths
and more than 9,000 sick people [1]. Up to now, it has become one
of the most important pathogens that caused food borne diseases.
Therefore, it is necessary to develop rapid, sensitive and specific
methods to detect E. coli O157:H7 in clinical or food samples
without further tedious and time consuming cultivation of the
bacterium. Immunological diagnostic methods, which utilize
specific antibody, were under consideration due to their simple
and rapid protocols. However, their efficacies mainly depend on the
quality of the specific monoclonal antibodies (mAbs). Ideally, mAbs
selected for use in E. coli O157:H7 detection should have no cross-
reactivity with other enterobacteria. However, E. coli O157:H7
share some common structural epitopes in its lipopolysaccharides
with Salmonella group N, Yersinia enterocolitica and other enterohemor-
rhagic E. coli, which may result to cross-reactions for E. coli
O157:H7 mAbs [2,3]. Sowers et al. investigated the specificity of
antisera for O157 and H7 referred by the Centers for Disease
Controland Prevention(CDC) anddemonstrated itsreactionwitha
strainofCitrobacter freundiiandallfour strains ofSalmonellaO groupN
(O30) [4]. Therefore, it is difficult to obtain a high specific antibody
against E. coli O157:H7.
Subtractive immunization (S.I.) is a proven technique to pre-
pare mAbs specific for antigens that are present in low abundance
in a protein mixture, poorly immunogenic and/or in similar
structure or sequence with other proteins [5]. It is generally per-
formed through a distinct immune tolerization approach that uses
the immunosuppressive agent Cyclophosphamide (Cy) coupled
with immunizations with two phenotypically distinct cell or pro-
tein variants as sequential immunogens. This procedure not only
eliminates the production of undesired mAbs, but also achieves
a highly specific antibody and increases the likelihood of ge-
nerating mAbs against rare or weakly immunogenic epitopes in
complex biological mixtures such as intact cells or tissues. There
are several unique reactive antibodies targeting special protein or
cells prepared successfully by this technique [6,7,8,9]. However,
to the best of our knowledge, there is so far no report on
the preparation of discriminatory mAbs for bacteria by this
procedure.
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7In the present article, we have generated a pool of mAbs by the
S.I.-hybridomas procedure. The mice were first immunized with
E. coli O157:H19, and subsequently with E. coli O157:H7. The
first and second immunizations were intervened by treatment
with the immunosuppressant drug, Cy. With this technique,
we prepared 3 specific mAbs exhibiting no cross-reactivity with
other non-E. coli O157:H7 targets. Compared with traditional
hybridoma technology, it is a rapid and efficient approach to




All animal procedures involving the care and use of animals
were in accordance with the regulations concerning the ethics of
science research in the Institute of Health and Environmental
Medicine and approved by the Ethics Review Board of Institute of
Health and Environmental Medicine (protocols #JKYSS-2007-
002 and #JKYSS-2007-003).
Bacterial Strains
The bacteria (listed in Table 1) grew on Trypticase soy
agar (TSA; BD Co.) or nutrition agar (NA; BD Co.) plates at
37QuCo v e r n i g h t .A l lt h es t a n d a r d strains were purchased
from China Medical Culture Collection (CMCC) or American
Type Culture Collection (ATCC). Some other E. coli strains
which included serotypes O26:H11 (IHEM 1.3035), O50:H7
(IHEM 1.3036), O111:H8 (IHEM 1.3037), and O145:NM
(IHEM 1.3038) were isolated from patients with hemolytic
uremic syndrome or hemorrhagic colitis and deposited in the
Microbiological Culture Collection Center of the Institute of
Health and Environmental medicine (IHME, Tianjin, China).
Whole-cell antigens were prepared using a previously described
method [10].
Subtractive Immunization Procedure
Six 5-week-old BALB/c mice were obtained from the Ex-
perimental Animal Center in the Academy of Military Medical
Sciences (Beijing, China). The S.I. procedure was performed as
follows according to Sleister and Rao’s protocol [5]. Briefly, on
day 1, 10
8 CFU E. coli O157:H19 (CMCC 44752) as tolerogen
were injected (intraperitoneal, i.p.). Cy (Sigma, USA) was injected
(100 mg per kg, i.p.) at 10 min, 24 hr and 48 hr later. The E. coli
O157:H19 and Cy injections cycle was repeated three other times
throughout a 14-day interval. On day 55, a tail bleed were co-
llected to detect Ab reactivity to E. coli O157:H19 in whole cell
ELISA. Once the mice had obtained the suppression capacity to
the antigenic determinants of the E. coli O157:H19, the mice were
further immunized as follows: 10
8 CFU E. coli O157:H7 (ATCC
43895) was injected (i.p.) intraperitoneally on day 55, 65, 72 and
86. On day 89, mice were sacrificed by cervical dislocation and
blood was collected through the orbital sinus after eyeball
extirpation. Spleen cells were harvested for the preparation of
hybridomas. In addition, five litter mate control mouse received
the same series of injections, except that the Cy-mediated tole-
rance procedure was omitted.
Construction of Hybridoma Cells
Fusions of Sp2/0 myeloma cells (China Center for Type Culture
Collection, CCTCC) with spleen cells from above immunized BALB/
c mice were performed according to Lane et al. [11]. Supernatants
from wells with hybridoma growth were screened for the production
of antibodies against E. coli O157:H7 and E. coli O157:H19 by
the indirect ELISA described below. Positive hybridoma cultures
were cloned by two cycles of cloning in limited dilution.





tested Collection or isolation source
a (serotype)
Escherichia coli TSA, 37uC2 6
Non O157 21 CMCC 44102, 44109, 44110, 44113, 44127(O14), 44149 (O127a:K63), 44155(O111:K58),
44156(O111:K58:H2), 44186(O26:K60), 44216(O14), 44505(O19b:H7), 44561(O128:K67:H2),
44813(O78:H11), 44824(O15:H21), 44825(O143), 44336(O55:K59:H6), 44338(O86a:K61);IHEM
1.3035(O26:H11),1.3036(O50:H7),1.3037(O111:H8),1.3038(O145:NM).
O157:H19 1 CMCC 44752
O157:H7 4 ATCC 43895; IHEM 1.3001,1.3002,1.3003.
Salmonella sp. TSA, 37uC 26 CMCC 50001, 50041, 50042, 50058, 50061, 50062, 50065, 50067, 50115, 50136, 50303, 50306,
50309, 50312, 50313, 0315, 50322, 50325, 50327, 50770, 50774, 50781, 50798, 50825, 50885,
50866
Shigella TSA, 37uC 18 CMCC 51510, 51512, 51513, 51514, 51515, 51516, 51517, 51518, 51519, 51521, 51522, 51524,
51361, 51499, 51135, 51066, 51067, 51081
Staphylococcus aureus NA, 37uC 4 CMCC 26003, 26071, 26113, 29213
Yersinia enterocolitica TSA, 37uC 4 CMCC 52215, 52216, 52219, 52243
Citrobacter freundii NA, 37uC 1 IHEM 1.5001
Klebsiella pneumoniae NA, 37uC 2 CMCC 46012; IHEM 1.6001
Proteus vulgaris NA, 37uC 1 CMCC 49001
Proteus morganii NA, 37uC 1 CMCC 49087
Proteus mirabilis NA, 37uC 1 CMCC 49106
a: CMCC, China Medical Culture Collection; ATCC, American Type Culture Collection; IHEM, Microbiological Culture Collection Center which belonged to the Institute of
Health and Environmental Medicine (Tianjin, China); TSA, Trypticase soy agar; NA, nutrition agar.
doi:10.1371/journal.pone.0031352.t001
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mAbs were produced by the in vitro and in vivo propagation of
hybridoma cells. In vitro cells were propagated in the RPMI-1640
medium (Gibco, USA) with 10% FBS. Harvested media were
centrifuged at 3,000 g for 30 min. Then, the supernatants were
collected and stored at 270uC. In vivo cells were propagated in 8-
week-old BALB/c mice to generate ascites fluid. The operating
procedure was carried out in accordance with Guidelines for
Monoclonal Antibody Production 2008 (NHMRC, http://www.ag.
gov.au/cca) and the ascites fluid was stored at 270uC until
purification.
Purification of mAbs
Following sequential precipitation with caprylic acid and
ammonium sulphate [12], the Protein A HP SpinTrap (GE
healthcare, USA) was used to purify mAbs from ascitic fluid
and cell culture supernatants according to the manufacturer’s
instructions.
Indirect ELISA
Indirect ELISA was used to assess the mAbs responses to
various bacteria [13]. To observe the specificity of the mAbs,
10
6 cfu of various tested bacteria diluted in carbonated-bicarbon-
ate buffer (50 mmol/L, pH 9.6) were added to 96-well microtiter
plates (Nunc, Denmark) and allowed to coat wells overnight at
4uC. To observe the sensitivity of the mAbs, the 96-well microtiter
plates were coated with 3610
1–3610
7 cfu E. coli O157:H7 diluted
in carbonated-bicarbonate buffer (50 mmol/L, pH 9.6) and
allowed to coat wells overnight at 4uC. Then, the plates were
washed three times with PBS containing 0.05% Tween 20 (PBS/
T) and blocked with PBS containing 1% bovine serum albumin
(Sigma, USA) for 1 h at 37uC. Following washing three times,
mAbs at various serial dilutions or PBS (negative control) were
added to each well and incubated for 1 h at 37uC. Plates were
washed with PBS/T three times and then incubated for 1 h at
37uC with horseradish peroxidase (HRP)-labeled rabbit anti-
mouse IgG (1:50000, Abcam, USA). After washing, substrate
solution (3,39,5,59-tetramethybenzidine) was added and the plate
was incubated at room temperature for 30 min. The colorimetric
reaction was interrupted with 2 mol/L sulphuric acid and the
optical density (OD) was recorded at 450 nm. A test sample was
considered positive if the ratio (T/C) of the OD value in the test
well (T) to that of the negative control well (C) was $2.1.
mAbs Isotyping
mAbs isotypes were determined using the Monoclonal antibody
Isotyping Kit I (Sigma, USA) by using indirect ELISA in which
10
6 cfu E. coli O157:H7 was coated on the 96-well microtiter
plates. The protocol was performed according to the manufactur-
er’s instructions.
Functional Affinity Constant of mAbs
The functional affinity constant of mAbs was determined
according to Loomans et al. [14] and the antibody dilutions re-
sulting in 50% of the maximum absorbance value at a particular
coating concentration were selected for the affinity calculation. It
was calculated according to Beatty et al. [15].
Western Blot Analysis
The recognized antigens of the mAbs were analyzed by western
blotting as previously described [13]. Briefly, fifty micrograms of E.
coli O157:H7 cell lysates (in 50 mmol/L Tris–HCl, pH 7.4, 1%
Triton X-100, 150 mmol/L NaCl, 1 mmol/L EDTA) were
separated by 10% SDS-PAGE, then transferred onto a nitrocel-
lulose membrane. Membranes were blocked with PBS containing
5% skimmed milk powder and 0.1% Tween 20 for 1 h at room
temperature. After washing, the membranes were placed into
a MiniProtean Multiscreen Apparatus (GE healthcare, USA).
Supernatants of different anti- E. coli O157:H7 cell-specific mAbs
were diluted 1:4 in blocking buffer and added to separate channels
in the apparatus, and incubated for 1 h at room temperature.
After five washes with 0.1% Tween20/PBS, membranes were then
incubated with HRP–conjugated goat anti-rabbit IgG (1:3000,
Abcam, USA) for 1 h at room temperature. After a further five
washes with 0.1% Tween 20/PBS, bound conjugate was detected
by Enhanced Chemiluminescence Reagent (GE healthcare, USA).
Preparation of Colloidal Gold Probe
The gold-labeled anti-E. coli O157:H7 mAbs conjugate was
prepared following the procedure described by Wang et al. [16].
The dispersion of colloidal gold particles was obtained by heating
a solution containing 0.01% AuCl3?HCl?4H2O (Sigma, USA) and
0.1% sodium citrate (Sigma, USA). The pH of the dispersed gold
solution was adjusted to 8.3 with 2% K2CO3 after the solution had
cooled. 150 mL of the purified anti-E. coli O157:H7 mAb (0.5 g/L)
were added to 10 mL colloidal gold solution. The mixture was
slowly stirred for 10 min then incubated overnight at 4uC without
stirring. The reaction mixture was centrifuged at 10,0006g for
60 min, 4uC and the precipitate was suspended in 1 mL
0.01 mol/L PBS/T (pH 7.4) containing 1% BSA, 0.02% NaN3
and 0.5% Tween-20.
Preparation of Food Samples Contaminated by Various
Pathogens
Minced beef was used as the food sample for examination of
various bacteria contaminations as described by Fukushima with
modifications [17]. Each 25 g minced beef and 10
9 CFU bacterial
solution listed in the Table 1 were mixed with 225 mL of 0.02%
Tween 20-buffered peptone water (Tween20-BPW) and homog-
enized in a stomacher 400 Circulator (Seward, English) for 1 min.
We added Tween 20 to BPW to emulsify fat in the samples.
Approximately 220 mL of filtration of the homogenates was
removed and then was centrifuged at 1,880 g for 5 min at room
temperature. The supernatant was transferred into a new tube and
then centrifuged at 16,000 g for 5 min at room temperature. The
final pellet was suspended in 1.5 mL of 0.15 mol/L NaCl and
used for sampling.
Dot-Immunogold Filtration Assay (DIGFA)
To rapidly detect E. coli O157:H7 in food samples, DIGFA, a
solid phase labelled immunoassay technique that uses a nitrocel-
lulose membrane (NCM) as a support and colloidal gold as the
label was performed according to Han et al. with modifications
[18]. Firstly, the NCM (Millipore, USA) was prepared by soaking
it with triple-distilled water and then air dried. The disc, 2 cm in
diameter, was made from the prepared membrane with a punch
and soaked in 0.05 mol/L carbonate buffer and then air-dried.
Secondly, E. coli O157:H7 was detected by dripping 2 mL of the
minced beef sample onto the disc. After this was air-dried, a 2 mL
of blocking agent (0.01 mol/L PBS containing 1% BSA, pH 7.4)
was added, followed by the addition of 5 mL of colloidal gold
probe. Finally, 10 mL of lotion (0.01 mol/L PBS containing 0.05%
Tween-20, pH 7.4) was added. Results were assessed by the
appearance of a reddish dot in the opening indicating a positive
reaction, whereas the absence of such a dot indicated a negative
reaction. A total of 2 mL of goat anti-mouse IgG replacing testing
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colloidal gold probe. The appearance of a reddish dot suggested
that this colloidal gold probe was indeed effective.
Results
Immune Suppression of E. coli O157:H19 by Cy
Treatment
The Cy-mediated S.I. strategy was used to suppress the immune
system of mice to the highly reactive immunodeterminants present on
E. coli O157:H19 that was inoculated as the initial immunogen
(experimental group). Sera from control mouse group (no Cy
treatment) exhibited a high antibody titer (about 1:10
4)w i t ht h eE.
coli O157:H19, while the sera from mice treated with Cy showed
negligible or no detectable reactivity on the E. coli O157:H19 (Fig. 1A).
Therefore, this indicated the mice had obtained the suppression
capacity to the antigenic determinants of the E. coli O157:H19.
Enhancement of Immune Response to E. coli O157:H7
On day 89, sera were collected and screened for reactivity to E.
coli O157:H7 and E. coli O157:H19 with indirect ELISA. The
control mice demonstrated higher antibody titers to E. coli
O157:H19 than to E. coli O157:H7 as indicated by low O157:
H7/O157:H19 ELISA ratios (Fig. 1B). On the contrary, the sera
from the mouse which had been treated with Cy after E. coli
O157:H19 inoculation, showed much lower reactivity towards E.
coli O157:H19 than to E. coli O157:H7 as their O157:H7/O157:
H19 ELISA ratio can reached up to 2.6. These data indicate that
Cy suppressed the immune response to E. coli O157:H19 sharply
and permittedan enhanceddifferential response to E. coliO157:H7.
Antigen Specificity and Sensitivity of mAbs from
Experimental Group
Nineteen hybridoma clones were generated from the above
experimental group mice after screening by indirect ELISA and
three times of subcloning, which were named as 1C6, 1D8, 1H6,
3F5, 3G12, 4A7, 4D7, 5A2, 5A5, 5A9, 5C12, 5D8, 5F10, 5F11,
5H4 , 6C11, 6D12, 7F1 and 7F8, respectively. The target antigen
specificity of mAbs from above selected clones was measured by
indirect ELISA with 84 strains of bacteria. mAbs from in vivo cells
of 1C6, 1D8, 1H6, 4A7, 5D8, 5A2 clones demonstrated good
quality, which had a titer of 1:2048 to E. coli O157 and negligible
reactivity towards other tested food-born pathogens including
Salmonella sp., Shigella sp., Proteus sp., Yersinia enterocolitica, Staphylococ-
cus aureus, Klebsiella pneumoniae, Citrobacter freundii and other non-E.
coli O157 enteric bacteria (Table 2). Above all, mAbs 1D8, 4A7,
5A2 produced from hybridomas in mouse ascites had a high titer
with E. coli O157:H7 (1:10
6), and showed no cross-reactivity with
all the other tested bacteria. In additions, their sensitivity to E. coli
O157:H7 can reach to 3610
4 cfu/mL. However, mAbs from
other clones including 3F5, 3G12, 4D7, 5A5, 5A9, 5C12, 5F10,
5F11, 5H4, 6C11, 6D12, 7F1 and 7F8 were showed to be un-
specific and react with several other non-targets (Table 2 and data
not shown). We also compared the specificity of our new an-
tibodies with a commercially available antibody against E. coli
O157:H7, the ab75244 from the Abcam, USA. The following
strains were tested including Salmonella sp. (CMCC 50325), Citro-
bacter freundii (IHEM 1.5001), Staphylococcus aureus (CMCC 29213),
Shigella (CMCC 51081,51066), Non-O157 E. coli (CMCC 44216,
44505), E. coli O157:H19 (CMCC 44752), E. coli O157:H7
(ATCC 43895). The ab75244 (1 mg/mL) exhibited high antibody
titers (about 1:16384) with both the E. coli O157:H7 and the E. coli
O157:H19. No cross-reactivity was found with other strains.
Therefore, the ab75244 is not able to discriminate E. coli O157:H7
from E. coli O157:H19, whereas our new mAbs 1D8, 4A7, 5A2
prepared by subtractive immunization distinguish E. coli O157:H7
from E. coli O157:H19 effectively.
Determination of Immunoglobulin Types and Functional
Affinity Constant of mAbs
The immunoglobulin typing of mAbs 1C6, 1D8, 4A7, 5A2 and
5D8 showed that the immunoglobulin subclass was IgM-type for
mAbs 1C6, 5A2, 5D8 clones and IgG type for 4A7 and 1D8
(Table 3). Moreover, based upon the analytical curve of affinity for
various mAbs, the mean Kaff for 5 mAbs ranged from 1.57610
10
to 1.47610
11 L/mol as listed in the Table 3.
Properties of the Antigens Recognized by the mAbs
To determine the nature of the antigens recognized by the
mAbs, total bacterial lysates were electrophoresed in non-reducing
Figure 1. Immune suppression of E. coli O157:H19 on day 55 and enhancement of immune response to E. coli O157:H7 on day 89 by
Cy-mediated subtractive immunization procedure. A, sera from Cy-treated mice (experimental group) and no Cy-treated mice (control group)
were diluted and tested for antibody reactivity to E. coli O157:H19 in whole cell ELISA (OD 450 nm); B, sera were diluted and tested for reactivity to
E. coli O157:H7 and E. coli O157:H19 (&: experimental group;N: control group).
doi:10.1371/journal.pone.0031352.g001
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5A2 and 5D8 recognized a single antigen of ,25 kDa. mAb
1C6 reacted with a major antigen of ,16.5 kD and a minor
immunoreactive antigen of ,20 kD. mAb 4A7 recognizes a major
antigen of ,24 kD and a minor immunoreactive antigen of
,28 kD. mAb 1D8 reacted with 3 antigens of different molecular
weights (Fig. 2). Therefore, it suggested that hybridoma lines 5A2
(5D8), 1C6, 4A7, 1D8 produced antibodies against different
localized antigens.
Detection of E. coli O157:H7 from Food Samples by
DIGFA
To further demonstrate the specificity of mAbs, 85 copies of
minced beef contaminated by single different bacteria listed in
the Table 1 were prepared and mAb 5A2 was used to detect E. coli
O157:H7 by DIGFA method. Immune-colloidal gold probe
coated with mAb 5A2 showed very good specificity and it singled
out food samples contaminated by E. coli O157:H7 rapidly (within
3 minutes) and accurately (Fig. 3). mAb 5A2 distinguished E. coli
O157:H7 specifically from 80 strains of Salmonella sp., Shigella sp.,
Proteus spp., Yersinia enterocolitica, Staphylococcus aureus, Klebsiella
pneumoniae, Citrobacter freundii and other non-E. coli O157:H7
enteric bacteria.
To validate the sensitivity of this method, different concentra-
tions of PBS-diluted E. coli O157:H7 which ranged from 10
5 to
10
9 CFU/mL was tested by DIGFA. This showed that its de-
tection limit reached 5.5610
6 cfu/mL.
Discussion
To detect food E. coli O157:H7 contamination rapidly and
accurately, Cy-mediated S.I. strategy has been employed in the
present study to obtain high specific mAbs 1D8, 4A7, 5A2.
The S.I. method has achieved the desired results in the pro-
duction of mAbs of different cells and proteins in the past decade
[6,7,8,9,19,20,21,22,23]. First, S.I. procedure provides a great new
approach for immunization workers to prepare mAbs with high
specificity. For example, Sakakibara et al. [7] found that the mAb
5H7-G1 generated by S.I. procedure could recognize egg antigens
in the animal cortex of fertilized, but not unfertilized, Xenopus eggs.
A S.I. strategy was also performed in rats to generate high specific
mAbs that preferentially reacted with antigens on ureteric bud, but
not adult inner medullary collecting duct cells [20]. Second, S.I.
procedure demonstrated subtractive immunization may work as
a strategy to uncover cellular events that operate during different
cellular conditions of interest. Rasmussen and Ditzel [9] described
a strategy producing a large panel of mAbs that recognized
cell surface markers preferentially or exclusively expressed on
Table 2. Summary of the characteristic of some mAbs reacting with Escherichia coli O157:H7 and others.
Organisms
No of strains
tested Positive strain number to be detected by mAbs
1C6 1D8 4A7 5A2 5D8 1H6 3G12 4D7
Escherichia coli 26
O157:H7 4 4 4 2 4 4 4 4 4
O157:H19 1 1 0 0 0 1 1 1 0
Non- O 1 5 7 2 1 0 0000045
Salmonella sp. 2 6 0 0000026
Shigella sp. 1 8 0 0000003
Proteus spp. 3 0 0000000
Yersinia enterocolitica 4 0 0000000
Staphylococcus aureus 4 0 0000021
Klebsiella pneumoniae 2 0 0000000
Citrobacter freundii 1 0 0000000
doi:10.1371/journal.pone.0031352.t002
Table 3. The characteristics of mAbs against E. coli O157:H7.












Figure 2. Protein antigens are detected by Western blot
analysis. E. coli O157:H7 cell lysates were subjected to SDS–PAGE,
transferred to nitrocellulose filter, and probed with 1C6 (lane 1), 1D8,
(lane 2), 4A7 (lane 3), 5A2 (lane 4), 5D8 (lane 5). The sizes of molecular
weight standards are shown at the right (lane 6).
doi:10.1371/journal.pone.0031352.g002
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ed the advantage of using the exquisitely discriminating recogni-
tion system of the immune system itself to scan the cell surface
proteome for differentially expressed proteins. Third, S.I. pro-
cedure increased the percentage of specific mAbs evidently. It was
reported by Ou et al. that the percentage of specific mAbs
increased by 7.5 times with the Cy-induced immune tolerance,
compared with the normal control group [24].
In general, the S.I. method was classified into three types
according to the tolerance approaches for the host animals in-
cluding high-zone tolerance, neonatal tolerance and drug tolerance
[25]. Not only will different tolerance procedures produce various
effects on the immune system of the host, but its subsequent
antibody production mechanism was also different. Many studies
have successfully taken the drug approach, especially Cy-mediated
tolerance with exclusive reactivity to a desired antigen, over the past
few years for its following advantages: (1) a mixture of tissue extracts
can be used directly to immunize mice which avoids the cum-
bersome process of antigen purification and the loss of antigen
activity; (2) mAbs can be prepared to distinguish between two
structurally similar proteins or tissues; (3) it reduces the amount
of tedious positive clone screening procedure; (4) Cy-mediated
tolerization is a immune response that is easy to experimentally
manipulate [26,27].
So far, there is no report about S.I. application in mAbs
production of bacteria. Although traditional hybridoma technol-
ogy has been widely used to generate mAbs for bacteria, there still
are some limitations in isolating specific antibodies for bacteria e.g.
E. coli O157:H7 whose specific antigen is present in a complex
mixture of proteins. Very few of the highly specific mAbs of E. coli
O157:H7 were reported by the hybridoma strategy. On the other
hand, the demand for highly specific mAbs of E. coli O157:H7 is
increasing due to minute changes between species and its frequent
outbreak in the past a couple of decades.
In this study, the method of S.I. by Cy-mediated tolerization
was adopted to generate antibodies against E. coli O157:H7 for the
first time. In general, donor mice are immunized first with the
control antigens (E. coli O157:H19), immediately followed by
treatment with the immunosuppressant drug, Cy. After these
treatments, the mice would induce no immune response to the first
antigens that act as tolerogens. Then, the same mice are
immunized with the second antigens (E. coli O157:H7) that have
very similar but distinct antigenic properties compared with the
first antigens. According to this scheme, highly specific mAbs that
preferentially reacted with antigens on E. coli O157:H7, but not E.
coli O157:H19 are generated. This not only ovecomes the problem
of the lack of specific antigen with high purity, but also increases
the likelihood of producing mAbs against rare or weakly
immunogenic epitopes, avoiding problems of poor immunogenic
small-molecule protein and antibody instability. Furthermore, this
procedure eliminates the production of undesired mAbs and helps
generate some unique mAbs which have no cross-reaction with
similar intestinal bacteria strains. In this study, the mAbs of 1D8,
4A7, 5A2 prepared by this strategy demonstrated no cross-
reactivity with Citrobacter freundii and Salmonella sp.. Furthermore,
preparing specific mAbs by the S.I. procedure is cost-efficient and
has high-throughput. In general, the traditional hybridoma
technology was laborious and lacked for preparing mAbs of
bacterium. Luciani et al. [28] prepared 101 mAbs of E. coli
O157:H7 using standard immunization, but there were only 7
specific antibodies which reacted with E. coli O157:H7 only and
not with the the 28 other bacterial antigens tested. In contrast,
according to the methods of subtractive immunization, we
screened 19 strains and found 3 mAbs of E. coli O157:H7 having
no cross-reactivity with 80 non-E. coli O157:H7 bacteria. Its
success ratio was 3/19, which was 3.8 times that of Lucinani’s
study [28].
In conclusion, highly specific mAbs against E. coli O157:H7 can
be produced by the subtractive immunization technique in mice
simply, rapidly and efficiently. Immune-colloidal gold probe
coated with mAb 5A2 detects E. coli O157:H7 contamination
from food samples rapidly and accurately by the DIGFA. Sub-
tractive immunization may play a vital role in the generation of
novel diagnostics mAbs in the future.
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